Rossiiskii immunologicheskii zhurnalIssue 4Optimization of Production Technology of Recombinant Human Interleukin-36 Receptor Antagonist for Use as Therapy for Severe Psoriasis
views: 1968
Readers community rating: votes 0
1. Garber C. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review / C. Garber, M. Creighton-Smith, E. P. Sorensen, N. Dumont, A. B. Gottlieb // J. Drugs Dermatol. JDD – 2015. – T. 14 – № 8–881–886 s.
2. López-Ferrer A. The safety of ustekinumab for the treatment of psoriatic arthritis / A. López-Ferrer, A. Laiz, L. Puig // Expert Opin. Drug Saf. – 2017. – T. 16 – № 6–733–742s.
3. Ryoo J. Y. Meta-analysis of the Effi cacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis / J. Y. Ryoo, H. – J. Yang, E. Ji, B. K. Yoo // Ann. Pharmacother. – 2016. – T. 50 – № 5–341–351s.
4. Setta-Kaff etzi N. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes / N. Setta-Kaff etzi, A. A. Navarini, V. M. Patel, V. Pullabhatla, A. E. Pink, S. – E. Choon, M. A. Allen, A. D. Burden, C. E. M. Griffi ths, M. M. B. Seyger, B. Kirby, R. C. Trembath, M. A. Simpson, C. H. Smith, F. Capon, J. N. Barker // J. Invest. Dermatol. – 2013. – T. 133 – № 5–1366–1369s.
